Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective

Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective

Objectives: The results of a CHOICE-1 study demonstrated the superior efficacy of toripalimab (anti-PD-1 antibody) plus chemotherapy for patients with advanced non–small cell lung cancer (NSCLC), with a manageable safety profile. This study was performed to evaluate the economic value of this treatm...

Full description

Bibliographic Details
Main Authors: Kexun Zhou, Pei Shu, Hanrui Zheng, Qiu Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Pharmacology
Subjects:
cost-effectiveness
toripalimab
chemotherapy
non-small cell lung cancer
Chinese payer’s perspective
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1133085/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1133085/full

Similar Items